Abstract
The recently licensed subunit hepatitis B vaccine (HEPTAVAX-B) is unique among vaccines in that it is manufactured solely from human plasma obtained from asymptomatic individuals with chronic hepatitis B. Plasma from donors selected for manufacturing this vaccine contains high concentrations of noninfectious hepatitis B surface antigen (HBsAg) particles and lower concentrations of infectious hepatitis B virus (HBV). The ratio of HBsAg to HBV can be as great as 10,000:1 (1). From the starting plasma, 22 nm spherical HBsAg particles are separated from HBV by ultracentrifugation. The 22 nm particles are then further purified by digestion with pepsin followed by the addition of 8M urea. Finally, the vaccine is treated with formaldehyde.
Chapter PDF
References
Gerety, R. J., Tabor, E., Purcell, R. H., et al. (1979). Summary of an international workshop on hepatitis B vaccines. J. Infect. Dis. 140:642–648.
Code of Federal Regulations, part 21, section 640. Government Printing Office, 1979.
FDA Guidelines: Clarification of Guidelines for Plasmapheresis of HBsAg Reactive Donors. Bethesda, MD, Food and Drug Administration, March 1981.
Hilleman, M. R., Buynak, E. B., McAleer, W. M., et al. (1982). Hepatitis A and hepatitis B vaccines, in Viral Hepatitis, 1981 International Symposium, W. Szmuness, H. J. Alter and J. E. Maynard, eds., Franklin Institute Press, Philadelphia, pp. 385–397.
Tabor, E., Buynak, E., Smallwood, L. A., et al. Inactivation of hepatitis B virus by three methods: Treatment with pepsin, urea, or formalin. J. Med. Virol., in press.
Buynak, E. B., Roehm, R. R., Tytell, A. A., et al. (1976). Development and chimpanzee testing of a vaccine against human hepatitis B. Proc. Soc.Exp. Biol. Med. 151:694–700.
Hilleman, M. R., Buynak, E. B., Roehm, R. R., et al. (1975). Purified and inactivated human hepatitis B vaccine: Progress report. Am. J. Med. Sci. 270:401–404.
Hunter, G. D., Gibbons, R. A., Kimberlin, R. H., et al. (1969). Further studies of the infectivity and stability of extracts and homogenates derived from scrapie affected mouse brains. J. Comp. Pathol. 79:101–108.
Tabor, E. and Gerety, R. J. (1980). Inactivation of an agent of human non-A, non-B hepatitis by formalin. J. Infect. Dis. 142:767–770.
Yoshizawa, H., Itoh, Y., Iwakiri, S., et al. (1982). Non-A, non-B (type 1) hepatitis agent capable of inducing tubular ultrastructures in the hepatocyte cytoplasm of chimpanzees: Inactivation by formalin and heat. Gastroenterology 82:502–506.
Szmuness, W., Stevens, C. E., Harley, E. J., et al. (1980). Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N. Engl. J. Med. 303:833–841.
Francis, D. P., Hadler, S. C., Thompson, S. E., et al. (1982). The prevention of hepatitis B with vaccine: Report of the CDC multi-center efficacy trial among homosexual men. Ann. Intern. Med. 97:362–366.
Hepatitis B virus vaccine safety: Report on an inter-agency group. (1982). MMWR 31:465–467.
Centers for Disease Control Special Report: Epidemiologic aspects of the current outbreak of Kaposi’s sarcoma and opportunistic infection. (1982). N. Engl. J. Med. 306:248–252.
Safai, B. and Good, R. A. (1981). Kaposi’s sarcoma: A review and recent developments. CA 31:2–12.
Drew, W. L., Conant, M. A., Miner, R. C., et al. (1982). Cytomegalovirus and Kaposi’s sarcoma in young homosexual men. Lancet 2:125–127.
Masur, H., Michelis, M. A., Greene, J. B., et al. (1981). An outbreak of community-acquired Pneumocystis carinii pneumonia: Initial manifestation of cellular immune dysfunction. N. Engl. J. Med. 305:1431–1438.
Friedman-Kien, A. E., Laubenstein, L. J., Rubinstein, P., et al. (1982). Disseminated Kaposi’s sarcoma in homosexual men. Ann. Intern. Med. 96:693–700.
Mildvan, D., Mathur, U., Enlow, R. W., et al. (1982). Opportunistic infection and immune deficiency in homosexual men. Ann. Intern. Med. 96:700–704.
Pneumocystis carinii pneumonia among persons with hemophilia A. (1982). MMWR 31:365–367.
Tabor, E. (1982). Infectious Complications of Blood Transfusion, Academic Press Inc., New York.
Krugman, S. (1982). The newly licensed hepatitis B vaccine: Characteristics and indications for use. JAMA 247:2012–2015.
Inactivated hepatitis B virus vaccine. (1982). MMWR 31: 318–328.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gerety, R.J. (1984). Newly Licensed Hepatitis B Vaccine. In: Millman, I., Eisenstein, T.K., Blumberg, B.S. (eds) Hepatitis B. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0369-3_15
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0369-3_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0371-6
Online ISBN: 978-1-4899-0369-3
eBook Packages: Springer Book Archive